Author: admin

Jim Breuer selected as Top Comedian of the Year by IAOTP

Jim Breuer selected as Top Comedian of the Year by IAOTP

Photo credit: Phil Provencio

Jim Breuer, infamous actor, producer, comedian, was recently selected as Top Comedian of the Year by the International Association of Top Professionals (IAOTP) for his outstanding leadership, dedication, and commitment to the industry.

Inclusion with the International Association of Top Professionals is an honor in itself; only a few members in each discipline are chosen for this distinction. These special honorees are distinguished based on their professional accomplishments, academic achievements, leadership abilities, longevity in the field, other affiliations, and contributions to their communities. All Honorees are invited to attend the IAOTP annual award gala at the end of this year for a night to honor their achievements.

www.iaotp.com/award-gala

With over three decades of experience, Mr. Breuer is an American actor, producer, podcast host, and comedian from New York. His acting and comedy career blew up when he started as a cast member on “Saturday Night Live” from 1995 to 1998, followed with his infamous performance in “Half Baked” in 1998.  At the time, he also began hosting “The Jim Breuer Show.”  Jim is also well known for his performances in “Zookeeper,” “Titan A.E.,” and “Dick.”  He has starred in numerous TV appearances in shows such as “Home Improvement” as well as doing the voices for numerous cartoon characters in shows such as “The Family Guy.” Jim was also a regular guest on “The Howard Stern Show” as well as Opie and Anthony’s morning show. In addition, he hosted MTV’s popular “Beach House” and VH1’s “Web Junk 20.” He was also featured on “Comedy Jam,” “This Is Not Happening,” “Late Night with Conan O’Brien,” “The Daily Show with Jon Stewart,” “The Late Late Show with Craig Ferguson,” “Jimmy Kimmel Live,” “Late Night with Jimmy Fallon,” and “The Marriage Ref.” He currently has a hit weekly podcast called, The Breuniverse, where he brings people from all walks of life together. He is a regular on “The Joe Rogan Experience.” In 2018-2019 Jim Breuer did a 36 city tour and the opening show for the Mega Band Metallica ! 

Jim’s standup comedy tackles all subjects from marriage and relationships to current events to love.  Jim is known for his skill at brilliantly pushing boundaries of political correctness to his animation in his performances. Jim is currently on tour as well and hotter than ever.  He is a global touring sensation and continues to have regular presence on radio and television.  He has a regular following who continues to show up to his performance live as well as on his Podcast.  See his website below for his tour dates.

Throughout his illustrious career, Mr. Breuer has received many awards and accolades and has been recognized worldwide for his accomplishments. He made the list of Comedy Central’s “100 Greatest Standups of All Time.” This year, he will be on the famous Nasdaq Billboard in Times Square NYC.  He is being considered for a feature in TIP (Top Industry Professionals) Magazine. He will be honored at IAOTP’s annual awards gala at Gaylord Opryland Resort in Nashville this December for his selection as Top Comedian of the Year.

In addition to his successful career, Mr. Breuer has donated money from his tours to help the homeless.  He also raised money for a family to offset medical bills when their mother had passed way.

The President of the International Association of Top Professionals (IAOTP), Stephanie Cirami, stated: “Choosing Mr. Breuer for this honor was an easy decision for our panel to make. He is inspirational, influential, and a true visionary and thought leader. We cannot wait to meet him and celebrate his accomplishments at this year’s gala.”

Looking back, Mr. Breuer attributes his success to his passion for what he does.  When not working, he enjoys spending time with his wife Dee and three daughters. Jim considers himself a modern-day dad, where he still has rock’n’roll in him, but takes being a parent and relationships very seriously in life. In the future, he hopes to inspire and influence those getting into the field.

For more information please visit:  https://www.jimbreuer.com/

About IAOTP

The International Association of Top Professionals (IAOTP) is an international boutique networking organization that handpicks the world’s finest, most prestigious top professionals from different industries.  These top professionals are given an opportunity to collaborate, share their ideas, be keynote speakers, and to help influence others in their fields. This organization is not a membership that anyone can join. You have to be asked by the President or be nominated by a distinguished honorary member after a brief interview.

IAOTP’s experts have given thousands of top prestigious professionals around the world, the recognition and credibility that they deserve and have helped in building their branding empires.  IAOTP prides itself to be a one-of-a-kind boutique networking organization that hand picks only the best of the best and creates a networking platform that connects and brings these top professionals to one place.

For More information on IAOTP please visit: www.iaotp.com

Media Contact
Company Name: IAOTP
Contact Person: Media Relations
Email: Send Email
Phone: (212) 634-4427
Country: United States
Website: https://iaotp.com

C.H. Hanson® and El Marko® “Now, Opening a Box Near You” with Innovative Bladeless Box Claw™

“The Box Claw’s patented design features a carefully engineered retractable bladeless claw mechanism that efficiently grabs and slices through packaging tape. It allows for a controlled and secure cutting experience, while considerably reducing the risk of accidental injuries to users or damage to merchandise that sometimes happens with bladed box openers.”
The patented Bladeless Box Claw™ from C.H. Hanson® and El Marko® tears through the old ways of package-opening and provides a more convenient solution. It prioritizes user safety without compromising performance.

NAPERVILLE, IL – Feb 28, 2024 – The box cutter in your grandpa’s tool chest is about to be retired from service and replaced by the new Box Claw™ from C.H. Hanson® and El Marko®.

Those risky old box cutters, featuring dangerous razor blades, are finally being upgraded to a better way of slicing through packing tape, reinforced tape, plastic wrapping and a variety of other packaging materials.

Prioritizing user safety without compromising performance, The Box Claw’s patented design features a carefully engineered retractable bladeless claw mechanism that efficiently grabs and slices through packaging tape. It allows for a controlled and secure cutting experience, while considerably reducing the risk of accidental injuries to users or damage to merchandise that sometimes happens with bladed box openers.

Ideal for use by both the lay person at home and professionals in commercial settings, the Box Claw also includes a welcome added feature and layer of versatility with its El Marko chiseled tip marker.

The permanent black chiseled tipped marker – located on the opposite end from the bladeless claw – is quick drying and smudge resistant and can be used on nearly all surfaces including wood, plastic, metal, concrete, leather and vinyl. The cap features a tight seal for a long-life and a built-in pocket clip for easy access.

The Box Claw measures six inches in length making it easy to use and convenient to store. By introducing a patented claw design, C.H. Hanson has successfully redefined the landscape of package opening tools. As consumers increasingly seek safer and ecologically friendly options, the Box Claw tears through the old ways of package-opening and provides a more convenient solution. Consumers no longer have to discard dangerous razor blades in the trash with this new product.

The Box Claw 2-in-1 Marker and Box Opener is exclusively available through C.H. Hanson.

Look for Box Claw at your local home center, hardware store and industrial supplier that carries C.H. Hanson products. It is available now. Ask for it by name!

Privately held and family-run for five generations, C.H. Hanson is one of the nation’s oldest manufacturers of marking and identification, cutting, layout, safety, and other non-powered hand tool products designed for use in the industrial, construction, safety, and hardware/DIY consumer markets. The company is recognized as an innovator of products and merchandising/retail solutions.

Media Contact
Company Name: C.H. Hanson
Contact Person: Marcie Harrison
Email: Send Email
Phone: 630-848-2000
Address:2000 N. Aurora Road
City: Chicago
State: IL 6056
Country: United States
Website: www.chhanson.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: C.H. Hanson® and El Marko® \”Now, Opening a Box Near You\” with Innovative Bladeless Box Claw™

Military Electro-Optics & Infrared (EO-IR) Systems Market to Hit US$ 17530 Million by 2030, Driven by 4.7% CAGR | The Market Reports

“Military Electro-Optics & Infrared (EO-IR) Systems Market Set to Exceed US$ 17530 Million by 2030, Driven by Growing Defense Investments”
The Military Electro-Optics & Infrared (EO-IR) Systems Market is anticipated to achieve a valuation of US$ 17530 million by 2030, exhibiting a remarkable Compound Annual Growth Rate (CAGR) of 4.7% during the forecast period from 2024 to 2030. This growth is propelled by increasing defense spending globally, coupled with the rising demand for advanced surveillance and reconnaissance capabilities.

Synopsis

The global Military Electro-Optics & Infrared Systems Market was valued at US$ 12620 million in 2023 and is anticipated to reach US$ 17530 million by 2030, witnessing a CAGR of 4.7% during the forecast period 2024-2030.

North American market for Military Electro-Optics & Infrared Systems is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Military Electro-Optics & Infrared Systems is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Military Electro-Optics & Infrared Systems include Raytheon, Thales Group, FLIR, BAE Systems, Unmanned Systems Source, UAV Propulsion Tech, Northrop Grumman, ELBIT Systems and Leonardo DRS, etc. In 2023, the world’s top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Military Electro-Optics & Infrared Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Military Electro-Optics & Infrared Systems.

Report Scope

The Military Electro-Optics & Infrared Systems market size, estimations, and forecasts are provided in terms of output/shipments (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Military Electro-Optics & Infrared Systems market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Military Electro-Optics & Infrared Systems manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, production, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Request a Sample Copy or Connect for Further Details: https://www.themarketreports.com/report/ask-your-query/1716820

Market Segmentation

By Company

  • Raytheon
  • Thales Group
  • FLIR
  • BAE Systems
  • Unmanned Systems Source
  • UAV Propulsion Tech
  • Northrop Grumman
  • ELBIT Systems
  • Leonardo DRS
  • General Dynamics
  • Safran Electronics & Defense

 

Segment by Type

  • Image Intensification
  • Laser and Infrared

 

Segment by Application

  • Air
  • Naval
  • Land

 

Production by Region

  • North America
  • Europe
  • China
  • Japan

 

Consumption by Region

  •  North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)

 

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Detailed analysis of Military Electro-Optics & Infrared Systems manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Production/output, value of Military Electro-Optics & Infrared Systems by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 4: Consumption of Military Electro-Optics & Infrared Systems in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 5: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 10: The main points and conclusions of the report.

Read More Related Research Reports:

Infrared Spectroscopy Market: https://www.themarketreports.com/report/global-infrared-spectroscopy-market-research-report

Mercury Cadmium Telluride Infrared Detector Market: https://www.themarketreports.com/report/global-mercury-cadmium-telluride-infrared-detector-market-research-report

Indium Gallium Arsenide Infrared Detector Market: https://www.themarketreports.com/report/global-indium-gallium-arsenide-infrared-detector-market-research-report

About US:

At ‘The Market Reports’, we are a trusted market research firm dedicated to empowering businesses with valuable insights and data to drive their success. We offer a wide range of comprehensive market research reports to meet the unique needs of each client. From market analysis and competitive intelligence to consumer behaviour and trend forecasting, we provide the critical information necessary to make informed decisions and stay ahead of the competition. Our goal is to empower our clients with the knowledge they need to drive growth, make strategic investments, and seize new opportunities.

Media Contact
Company Name: The Market Reports
Contact Person: Shirish Gupta
Email: Send Email
Phone: +16314071315
Address:SF-29, Sacred World, Wanawadi
City: Pune
State: Maharastra
Country: India
Website: https://www.themarketreports.com/report/global-military-electro-optics-infrared-systems-market-research-report

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Military Electro-Optics & Infrared (EO-IR) Systems Market to Hit US$ 17530 Million by 2030, Driven by 4.7% CAGR | The Market Reports

ZTE Launches Intelligent Computing Solutions at MWC Barcelona 2024

At the MWC Barcelona 2024, ZTE Corporation unveiled its latest endeavor in intelligent computing solutions. This strategic move is designed to propel digital and intelligent transformation across various sectors, marking a significant milestone in the industry’s evolution towards a more interconnected and smart future.

MWC Barcelona 2024: ZTE’s Full-Stack Computing Infrastructure

ZTE has developed a full-stack computing infrastructure that addresses the increasing need for diverse computing power and high energy efficiency. The infrastructure provides end-to-end solutions that include heterogeneous computing power, high-performance storage, lossless networks, and fully liquid-cooled data centers. The aim is to cater to the requirements of both general and intelligent computing scenarios across various industries.

AiCube All-in-One Cabinet

ZTE’s AiCube is an innovative all-in-one cabinet solution that revolutionizes edge computing. It is a compact and powerful device that integrates AI computing, storage, network, and AI platform software into a single package.

One of the most significant advantages of the AiCube is that it supports mainstream AI frameworks, including TensorFlow, PyTorch, and Caffe. This significantly reduces the training and inference costs for private field AI models. The device also lowers technical barriers for businesses that want to develop and deploy AI models for specific applications. 

AiCube also enhances enterprise data security by keeping sensitive data within the company’s premises. The device has advanced security features that protect against data breaches or cyber-attacks.

IceCube High-Density Full Liquid-Cooled Cabinet

IceCube is a high-density, fully liquid-cooled cabinet set to revolutionize the green data center space. It is the perfect blend of innovation, performance, and sustainability. It is designed to cater to the ever-growing demand for more efficient and eco-friendly data centers.

With the ability to house up to 40 1U servers, the IceCube boasts unparalleled computing density and efficiency. This is achieved through its unique blind mating design and highly efficient liquid cooling cabin doors. These help the data center achieve an impressive pPUE of less than 1.1. This is remarkable compared to traditional data centers. Typically, traditional data centers have a pPUE of around 1.5-2.0.

The IceCube’s design also ensures that the cabinet’s doors remain closed, preventing air leaks. The liquid cooling cabin doors effectively remove heat from the servers and transfer it to the liquid coolant.  

ZTE has created a product that helps reduce carbon emissions and energy consumption. With the IceCube, data center operators can enjoy reduced operating costs, improved energy efficiency, and a reduced environmental footprint.

AI Booster Intelligent Computing Platform

The AI Booster Intelligent Computing Platform is a cutting-edge solution revolutionizing how businesses utilize artificial intelligence. The platform aims to simplify and optimize the use of AI technologies, making them more accessible and efficient.   

The AI Booster platform optimizes GPU utilization for faster and more efficient AI model training. Using automatic parallel training optimizes computational resources, reducing the time and resources required for AI model development. The platform simplifies development and training by incorporating visual development tools and a zero-code design interface. 

Another standout feature of the AI Booster is its self-adaptive parameter optimization. This automates the fine-tuning of AI models. This ensures you achieve the best possible performance with minimal human intervention.

By simplifying the optimization process, ZTE’s platform helps businesses scale their AI solutions and remain competitive.

MWC24: ZTE Generative AI to All Scenarios

ZTE’s innovative approach to integrating Generative AI in various scenarios demonstrates its dedication to improving industry efficiency and leading modernization efforts.

Research and Development

ZTE is transforming the Research and Development sector by introducing a coding assistant application powered by Nebula Encoding’s large model. This advanced tool enhances developers’ capabilities and streamlines the coding processes. Thus, reducing time spent on routine tasks such as debugging.

The outcome is a significant 20% improvement in overall research and development efficiency, which facilitates faster innovation cycles and the rapid development of cutting-edge solutions.

Telecommunications

ZTE, a leader in the telecom industry, has achieved a significant breakthrough by enabling the commercial use of autonomous networks. This was made possible by deploying the Nebula telecommunication large model, marking the industry’s first smart event. The autonomous network uses advanced AI algorithms and can self-optimize, self-healing, and predictive maintenance.

This results in enhanced network reliability, reduced downtime, and improved user service quality. This initiative highlights ZTE’s leadership in telecom innovation and contributes to the evolution of smarter, more efficient telecommunication infrastructure.

Industrial

Implementing the Nebula CV (Computer Vision) model significantly advances Industrial Parks to improve security and operational efficiency. ZTE applies this advanced model to campus-wide security systems, supporting multiple security operation scenarios. This includes surveillance, access control, incident detection, and response.

Adopting the Nebula CV model results in an impressive 35% increase in overall operation efficiency, demonstrating the powerful capabilities of AI in streamlining processes, enhancing safety measures, and ensuring a secure environment for industrial activities.

ZTE is making significant strides at MWC Barcelona 2024 by introducing a comprehensive computing infrastructure that is powered by AI innovations. This marks a significant shift towards enhancing industry efficiency and modernization. By strategically applying generative AI across various sectors, ZTE is not just shaping the future of technology but also empowering industries to embrace a smarter and more efficient tomorrow.

Media Contact
Company Name: ZTE Corporation
Contact Person: Lunitta LU
Email: Send Email
Country: China
Website: https://www.zte.com.cn/global/

Primary Hyperoxaluria Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Alnylam Pharma, Genentech, Dicerna Pharma, Pfizer

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Primary Hyperoxaluria pipeline constitutes 8+ key companies continuously working towards developing 8+ Primary Hyperoxaluria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Primary Hyperoxaluria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Primary Hyperoxaluria Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Hyperoxaluria Market.

 

Some of the key takeaways from the Primary Hyperoxaluria Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Primary Hyperoxaluria treatment therapies with a considerable amount of success over the years. 
  • Primary Hyperoxaluria companies working in the treatment market are Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others, are developing therapies for the Primary Hyperoxaluria treatment 
  • Emerging Primary Hyperoxaluria therapies in the different phases of clinical trials are- CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others are expected to have a significant impact on the Primary Hyperoxaluria market in the coming years.   
  • In September 2022, Novo Nordisk has presented Nedosiran to the FDA in the United States for regulatory consideration.
  • In February 2022, Dicerna Pharmaceuticals, Inc. has commenced a Phase II open-label multicenter investigation to assess the safety, pharmacokinetics, and effectiveness of Nedosiran in pediatric patients ranging from birth to 11 years old, specifically those diagnosed with primary hyperoxaluria and possessing relatively preserved renal function.

 

Primary Hyperoxaluria Overview

Primary Hyperoxaluria (PH) is a rare genetic disorder characterized by the overproduction of oxalate, a substance that is normally eliminated through the kidneys in the urine. In individuals with Primary Hyperoxaluria, there is a defect in the liver enzymes responsible for breaking down glyoxylate, leading to an accumulation of oxalate in the body.

 

Get a Free Sample PDF Report to know more about Primary Hyperoxaluria Pipeline Therapeutic Assessment

https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight

 

Emerging Primary Hyperoxaluria Drugs Under Different Phases of Clinical Development Include:

  • CHK-336: Chinook Therapeutics
  • BBP-711: Cantero Therapeutics
  • BMN 255: BioMarin Pharmaceutical, Inc
  • Oxabact: OxThera
  • Nedosiran: Dicerna Pharmaceuticals, Inc.

 

Primary Hyperoxaluria Route of Administration

Primary Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

 

Primary Hyperoxaluria Molecule Type

Primary Hyperoxaluria Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Primary Hyperoxaluria Pipeline Therapeutics Assessment

  • Primary Hyperoxaluria Assessment by Product Type
  • Primary Hyperoxaluria By Stage and Product Type
  • Primary Hyperoxaluria Assessment by Route of Administration
  • Primary Hyperoxaluria By Stage and Route of Administration
  • Primary Hyperoxaluria Assessment by Molecule Type
  • Primary Hyperoxaluria by Stage and Molecule Type

 

DelveInsight’s Primary Hyperoxaluria Report covers around 8+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Primary Hyperoxaluria product details are provided in the report. Download the Primary Hyperoxaluria pipeline report to learn more about the emerging Primary Hyperoxaluria therapies

 

Some of the key companies in the Primary Hyperoxaluria Therapeutics Market include:

Key companies developing therapies for Primary Hyperoxaluria are – Alnylam Pharmaceuticals, Inc., Genentech, Inc., Dicerna Pharmaceuticals, Inc., Pfizer Inc., Zhejiang Tianxin Pharmaceutical Co., Wuxi Further Pharmaceutical Co Ltd, Tecoland Corporation, Takeda Pharmaceuticals Company Limited, Intellia Therapeutics, Inc., and others.

 

Primary Hyperoxaluria Pipeline Analysis:

The Primary Hyperoxaluria pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Primary Hyperoxaluria with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Hyperoxaluria Treatment.
  • Primary Hyperoxaluria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Primary Hyperoxaluria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Hyperoxaluria market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Primary Hyperoxaluria Pipeline Market Drivers

  • Rising Prevalence of Primary hyperoxaluria, increasing demand of disease specific novel treatment are some of the important factors that are fueling the Primary Hyperoxaluria Market.

 

Primary Hyperoxaluria Pipeline Market Barriers

  • However, high cost of treatment and diagnosis for Hyperoxaluria, limited research and development for treatment and other factors are creating obstacles in the Primary Hyperoxaluria Market growth.

 

Scope of Primary Hyperoxaluria Pipeline Drug Insight    

  • Coverage: Global
  • Key Primary Hyperoxaluria Companies: Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others
  • Key Primary Hyperoxaluria Therapies: CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others
  • Primary Hyperoxaluria Therapeutic Assessment: Primary Hyperoxaluria current marketed and Primary Hyperoxaluria emerging therapies
  • Primary Hyperoxaluria Market Dynamics: Primary Hyperoxaluria market drivers and Primary Hyperoxaluria market barriers 

 

Request for Sample PDF Report for Primary Hyperoxaluria Pipeline Assessment and clinical trials

 

Table of Contents

1. Primary Hyperoxaluria Report Introduction

2. Primary Hyperoxaluria Executive Summary

3. Primary Hyperoxaluria Overview

4. Primary Hyperoxaluria- Analytical Perspective In-depth Commercial Assessment

5. Primary Hyperoxaluria Pipeline Therapeutics

6. Primary Hyperoxaluria Late Stage Products (Phase II/III)

7. Primary Hyperoxaluria Mid Stage Products (Phase II)

8. Primary Hyperoxaluria Early Stage Products (Phase I)

9. Primary Hyperoxaluria Preclinical Stage Products

10. Primary Hyperoxaluria Therapeutics Assessment

11. Primary Hyperoxaluria Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Primary Hyperoxaluria Key Companies

14. Primary Hyperoxaluria Key Products

15. Primary Hyperoxaluria Unmet Needs

16 . Primary Hyperoxaluria Market Drivers and Barriers

17. Primary Hyperoxaluria Future Perspectives and Conclusion

18. Primary Hyperoxaluria Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Hyperoxaluria Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Alnylam Pharma, Genentech, Dicerna Pharma, Pfizer

Anti-CD20 Antibody Pipeline Outlook Report 2024

DelveInsight’s, “Anti-CD20 Antibody Pipeline Insight 2024” report provides comprehensive insights about 20+ Anti-CD20 Antibody companies and 20+ pipeline drugs in Anti-CD20 Antibody pipeline landscape. It covers the Anti-CD20 Antibody pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anti-CD20 Antibody pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Anti-CD20 Antibody Pipeline Report

  • DelveInsight’s Anti-CD20 Antibody pipeline report depicts a robust space with 20+ Anti-CD20 Antibody companies working to develop 20+ pipeline therapies for Anti-CD20 Antibody treatment.
  • The leading companies working in the Anti-CD20 Antibody market include TG Therapeutics, Roche, Genmab/ Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencorm, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera solutions, and others.
  • Promising Anti-CD20 Antibody Pipeline Therapies in the various stages of development include Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab, Ofatumumab, Cyclophosphamide, Doxorubicin, Acalabrutinib, Obinutuzumab and Pixantrone, and others.
  • On July 2023, University of Washington announced a study of Phase 2 Clinical Trials for Obinutuzumab, Rituximab, and Pembrolizumab. This phase II trial studies how well pembrolizumab with rituximab or obinutuzumab work in treating patients with follicular lymphoma or diffuse large B cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory).
  • On July 2023, Cho Pharma Inc. announced a study of Phase 1 & 2 Clinical Trials for CHO-H01. This is a 2-part study. Part 1/Phase 1 of the study will be conducted to determine the safety and tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin’s lymphoma. It will also determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D).
  • On August 2023, BeiGene announced a study of Phase 3 Clinical Trials for Zanubrutinib, Rituximab, Lenalidomide, and Obinutuzumab. The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

 

Request a sample and discover the recent advances in Anti-CD20 Antibody Treatment Drugs @ Anti-CD20 Antibody Pipeline Report

 

The Anti-CD20 Antibody pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Anti-CD20 Antibody drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Anti-CD20 Antibody clinical trial landscape.

 

Anti-CD20 Antibody Overview

CD20 is a 33- to 37-kDa non-glycosylated phosphoprotein expressed on the surface of mature undifferentiated B-cells. Expression starts at the pre–B-cell stage, and persists until terminal differentiation into plasma cells.

 

Find out more about Anti-CD20 Antibody Treatment Landscape @ Drugs for Anti-CD20 Antibody Treatment

 

Anti-CD20 Antibody Emerging Drugs Profile

  • Ublituximab: TG therapeutics
  • Glofitamab: Roche

 

Anti-CD20 Antibody Pipeline Therapeutics Assessment

The Anti-CD20 Antibody pipeline report proffers an integral view of the Anti-CD20 Antibody emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging Anti-CD20 Antibody Pipeline Therapies @ Anti-CD20 Antibody Clinical Trials Assessment

 

Scope of the Anti-CD20 Antibody Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Anti-CD20 Antibody Companies- TG Therapeutics, Roche, Genmab/ Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencorm, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera solutions, and others.
  • Anti-CD20 Antibody Pipeline Therapies- Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab, Ofatumumab, Cyclophosphamide, Doxorubicin, Acalabrutinib, Obinutuzumab and Pixantrone, and others.

 

Dive deep into rich insights for new drugs for Anti-CD20 Antibody Treatment, Visit @ Anti-CD20 Antibody Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Anti-CD20 Antibody: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Anti-CD20 Antibody – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Anti-CD20 Antibody Collaboration Deals
  9. Late Stage Products (Preregistration)
  10. Ublituximab: TG therapeutics
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Odronextamab: Regeneron Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early stage products (Phase I)
  16. IGM 2323: IGM Biosciences
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Anti-CD20 Antibody Key Companies
  20. Anti-CD20 Antibody Key Products
  21. Anti-CD20 Antibody- Unmet Needs
  22. Anti-CD20 Antibody- Market Drivers and Barriers
  23. Anti-CD20 Antibody- Future Perspectives and Conclusion
  24. Anti-CD20 Antibody Analyst Views
  25. Anti-CD20 Antibody Key Companies
  26. Appendix

  

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anti-CD20 Antibody Pipeline Outlook Report 2024

Advanced Merkel Cell Carcinoma Pipeline Outlook Report 2024

DelveInsight’s, “Advanced Merkel cell carcinoma Pipeline Insight 2024″ report provides comprehensive insights about 20+ Advanced Merkel Cell Carcinoma Companies and 20+ pipeline drugs in the Advanced Merkel cell carcinoma pipeline landscape. It covers the Advanced Merkel Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Merkel Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Advanced Merkel Cell Carcinoma Pipeline Report

  • DelveInsight’s Advanced Merkel Cell Carcinoma pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Advanced Merkel Cell Carcinoma treatment.
  • The leading companies working in the Advanced Merkel Cell Carcinoma market include Xencor Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis Inc., Checkpoint Therapeutics, Inc., and others.
  • Promising Advanced Merkel Cell Carcinoma Pipeline Therapies in the various stages of development include Pembrolizumab (MK-3475), Avelumab, Cemiplimab-Rwlc, FF-10850 Topotecan Liposome Injection, IFx-Hu2.0, Vidutolimod, Cemiplimab, INCB099318, SO-C101, CK-301 (cosibelimab), and others.
  • December 2023: Regeneron Pharmaceuticals announced a study of Phase 2 clinical trials for vidutolimod and cemiplimab. The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have an end of treatment visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.
  • December 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Pembrolizumab (MK-3475). This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial is to assess the objective response rate, as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, following administration of pembrolizumab.
  • On August 2023, H. Lee Moffitt Cancer Center and Research Institute announced a study of Phase 1 Clinical Trials for Cemiplimab-Rwlc. The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).
  • On July 2023, 4SC AG announced a study of Phase 2 Clinical Trials for Domatinostat in Combination with Avelumab. This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with an anti-PD-(L)1 antibody.
  • On June 2023, Memorial Sloan Kettering Cancer Center announced a study of Phase 2 Clinical Trials for Avelumab. This study will test the use of comprehensive ablative radiation therapy (CART), with the immunotherapy drug avelumab, in people with Merkel cell carcinoma (MCC) that has progressed after treatment and cannot be removed with surgery. The study researchers want to find out if CART works well when combined with avelumab.
  • On February 2023, Merck Sharp & Dohme LLC announced a study of Phase 3 Clinical Trials for Pembrolizumab (MK-3475). This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial is to assess the objective response rate, as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, following administration of pembrolizumab.

 

Request a sample and discover the recent advances in Advanced Merkel Cell Carcinoma Treatment Drugs @ Advanced Merkel Cell Carcinoma Infection Pipeline Report

 

The Advanced Merkel Cell Carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Merkel Cell Carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Merkel Cell Carcinoma clinical trial landscape.

 

Advanced Merkel Cell Carcinoma Overview

Advanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease.

 

Find out more about Advanced Merkel Cell Carcinoma Treatment Drugs @ Drugs for Advanced Merkel Cell Carcinoma Treatment

 

Advanced Merkel Cell Carcinoma Emerging Drugs Profile

  • Tidutamab: Xencor, Inc.
  • Cabozantinib: Exelixis

 

Advanced Merkel Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Advanced Merkel cell carcinoma. The Advanced Merkel Cell Carcinoma companies which have their Advanced Merkel cell carcinoma drug candidates in the most advanced stage, i.e. phase II include, Exelixis.

 

Learn more about the emerging Advanced Merkel Cell Carcinoma Pipeline Therapies @ Advanced Merkel Cell Carcinoma Clinical Trials Assessment

 

Scope of the Advanced Merkel Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Advanced Merkel Cell Carcinoma Companies- Xencor Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis Inc., Checkpoint Therapeutics, Inc., and others.
  • Advanced Merkel Cell Carcinoma Pipeline Therapies- Pembrolizumab (MK-3475), Avelumab, Cemiplimab-Rwlc, FF-10850 Topotecan Liposome Injection, IFx-Hu2.0, Vidutolimod, Cemiplimab, INCB099318, SO-C101, CK-301 (cosibelimab), and others.

 

Dive deep into rich insights for new drugs for Advanced Merkel Cell Carcinoma treatment, Visit @ Advanced Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Merkel cell carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Merkel cell carcinoma – DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Phase II)
  8. Cabozantinib: Exelixis
  9. Drug profiles in the detailed report…..
  10. Early Stage Products (Phase I)
  11. IFx-Hu2.0: Morphogenesis
  12. Drug profiles in the detailed report…..
  13. Inactive Products
  14. Advanced Merkel cell carcinoma Key Companies
  15. Advanced Merkel cell carcinoma Key Products
  16. Advanced Merkel cell carcinoma- Unmet Needs
  17. Advanced Merkel cell carcinoma- Market Drivers and Barriers
  18. Advanced Merkel cell carcinoma- Future Perspectives and Conclusion
  19. Advanced Merkel cell carcinoma Analyst Views
  20. Advanced Merkel cell carcinoma Key Companies
  21. Appendix

 

For further information on the Advanced Merkel Cell Carcinoma pipeline therapeutics, reach out to Advanced Merkel Cell Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Merkel Cell Carcinoma Pipeline Outlook Report 2024

Thyroid Cancer Pipeline Insights Report 2024

DelveInsight’s, “Thyroid Cancer Pipeline Insight 2024” report provides comprehensive insights about 40+ Thyroid Cancer companies and 40+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Thyroid Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Thyroid Cancer Pipeline Report

  • DelveInsight’s Thyroid Cancer Pipeline analysis depicts a robust space with 40+ active players working to develop 40+ pipeline treatment therapies.
  • The leading companies working in the Thyroid Cancer Market include Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.
  • Promising Thyroid Cancer Pipeline Therapies in the various stages of development include Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
  • December 2023: Novartis Pharmaceuticals announced a study of Phase 3 clinical trials for Trametinib and Dabrafenib. This is a global, multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in adult patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid cancer who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy.
  • November 2023: Affylmmune Therapeutics Inc. announced a study of Phase 1 clinical trials for AIC100 CAR T Cells. The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.
  • In July 2023, Eisai Limited announced a study of phase 1 & 2 clinical trials for Lenvatinib, Ifosfamide, and Etoposide. This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid malignancies including differentiated thyroid carcinoma (single agent lenvatinib) and osteosarcoma (single agent and combination lenvatinib).
  • On January 2023, Famewave Ltd announced a study of phase 1 & 2 clinical trials for Nivolumab and Nal-IRI/5-FU/LV – Expansion. This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C & D) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV will be administered subsequent to CM24 and nivolumab. CM24, nivolumab and gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV are administered intravenously.

 

Request a sample and discover the recent advances in Thyroid Cancer Treatment Drugs @ Thyroid Cancer Pipeline Outlook Report

 

In the Thyroid Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Thyroid Cancer Overview

Thyroid cancer starts in the cells that make up your thyroid gland. The thyroid gland makes hormones that help control many processes in your body. Thyroid cancer is relatively common enough so that all of us will know somebody with thyroid cancer. There are more than 50,000 new cases of thyroid cancer each year in the United States. Women are more likely to develop thyroid cancer at a ratio of three to one.

 

Find out more about Thyroid Cancer Therapeutics Assessment @ Thyroid Cancer Preclinical and Discovery Stage Products

 

Thyroid Cancer Emerging Drugs Profile

  • Donafenib: Suzhou Zelgen Biopharmaceuticals
  • Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical
  • Nivolumab: Bristol-Myers Squibb
  • RX208: Suzhou NeuPharma
  • AIC100: AffyImmune Therapeutics

 

Thyroid Cancer Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the Thyroid Cancer therapies. The Thyroid Cancer companies which have their Thyroid Cancer drug candidates in the most advanced stage, i.e. phase III include, Suzhou Zelgen Biopharmaceuticals.

 

Request a sample and discover the recent advances in Thyroid Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Thyroid Cancer Segmentation

 

Thyroid Cancer Drugs and Companies

  • Rosiglitazone: Exelixis
  • Lenvatinib: Eisai Limited
  • Ifosfamide: Merck Sharp & Dohme LLC

 

Thyroid Cancer Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Some of the Companies in the Thyroid Cancer Therapeutics Market include-

Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.

 

Dive deep into rich insights for drugs for Thyroid Cancer Pipeline, click here @ Thyroid Cancer Unmet Needs and Analyst Views

 

Scope of the Thyroid Cancer Pipeline Report

  • Coverage- Global
  • Thyroid Cancer Companies- Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.
  • Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
  • Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Thyroid Cancer Merger and acquisitions, Licensing Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Thyroid Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Thyroid Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Donafenib: Suzhou Zelgen Biopharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Nivolumab: Bristol-Myers Squibb
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AIC100: Affyimmune Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Thyroid Cancer Key Companies
  21. Thyroid Cancer Key Products
  22. Thyroid Cancer- Unmet Needs
  23. Thyroid Cancer- Market Drivers and Barriers
  24. Thyroid Cancer- Future Perspectives and Conclusion
  25. Thyroid Cancer Analyst Views
  26. Thyroid Cancer Key Companies
  27. Appendix

  

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thyroid Cancer Pipeline Insights Report 2024

COVID-19 Competitive Landscape 2023 (Updated)

DelveInsight’s, “COVID-19 Competitive Landscape 2023” report provides comprehensive insights about 400+ COVID-19 Companies and 500+ drugs in Covid-19 Competitive landscape. It covers the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the COVID-19 Report

  • DelveInsight’s COVID-19 report depicts a robust space with 400+ active players working to develop 500+ pipeline therapies for COVID-19 treatment.
  • The leading companies working in the COVID-19 Market include Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, Inc., Valneva, Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories, UNION Therapeutics, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma, TC BioPharm, Syntax for Science, S.L, SyneuRx, Swedish Orphan Biovitrum, Swedish Herbal Institute AB, Stemedica Cell Technologies, Staidson (Beijing) Biopharmaceuticals Co., Ltd, Sound Pharmaceuticals, Sorrento Therapeutics, SolAeroMed, SK Bioscience, Sinovac Biotech Co., Ltd, Sinocelltech, Shenzhen Kangtai Biological Products Co., Ltd., Shaperon, Senhwa Biosciences, Inc., Selva Therapeutics, Archivel Farma, R-Pharm, Rohto Pharmaceutical, Revimmune, Resverlogix Corporation, Restorbio, Resolve Therapeutics, Renibus Therapeutics, ReiThera, Regeneron Pharmaceuticals, RedHill Biopharma, Red de Terapia Celular, Reata Pharmaceuticals, Inc., Qurient Co, Quercis Pharma, PureTech, Pulmotect, PTC Therapeutics, Pluristem Ltd., Pliant Therapeutics, Pharming Technologies B.V., Pharmenterprises, Pharmamel S.L., Pharma Holdings, Pharco Pharmaceuticals, Pfizer, Petrovax, Paion UK Ltd., Ashvattha Therapeutics, Inc. (Orpheris), OPKO Health, Oncotelic Inc., National Resilience, Inc. (Ology Bioservices), Olatec Therapeutics LLC, Novavax, Novartis Pharmaceuticals, Notitia Biotechnologies Company, Noorik Biopharmaceuticals, Nobelpharma, Moderna, Moderna, MetrioPharm, Merck Sharp & Dohme Corp., Merck KGaA, Medicago Inc., Mallinckrodt, Mabwell (Shanghai) Bioscience Co., Ltd., Lifefactors Zona Franca, Leading BioSciences, Kiniksa Pharmaceuticals, Ltd., 3M, 4D Pharma, AbbVie, Apotex, AgelessRx, AgenTus Therapeutics, AiCuris, AlloVir, Apeiron Biologics, Bausch Health Americas, BeiGene, Biotest, Bio-Thera Solutions, Cadila Healthcare Limited, Cellenkos, Cellularity Incorporated, Chiesi Farmaceutici S.p.A., Clene Nanomedicine, Codagenix, Debiopharm, Direct Biologics, Eiger BioPharmaceuticals, Emergent Biosolutions, Enlivex Therapeutics, Evergreen Therapeutics, Faron Pharmaceuticals, Frontier Biotechnologies, FSD Pharma, Genentech, Inc., Globavir Biosciences, Grand Medical, Grifols Therapeutics LLC, Inotrem, Ionis Pharmaceuticals, Jazz Pharmaceuticals, Kamada, Kiadis Pharma, Medicine Invention, MedRegen LLC, Miltenyi Biomedicine, Natureceuticals Sdn Bhd, NeoImmune Tech, Neutrolis, Ology Bioservices, Oncovir, OPKO Health, Organicell Regenerative Medicine, and others.
  • Promising COVID-19 therapies in the various stages of development includes XAV-19, Sinapultide, VIR-7831, Maraviroc, Duvelisib, VB 201, AV-001, VLA2001, T3 solution for injection, UNIKINON, UNI911, Umbilical cord derived mesenchymal stem cells, MAD0004J08, Stem Cell Educator therapy, RESP301, TD-0903, TCB008, Bemiparin, Pentarlandir™ UPPTA, Emapalumab, Kan Jang capsules, hMSC, BDB-001, Ebselen, COVI-DROPS| Placebo, STI-5656, COVI-AMG, PSC-04, S-1226, GBP510, SARS-COV-2 inactivated vaccine, SCTA01, SARS-CoV-2 Vaccine (Vero Cells), Inactivated, NuSepin, Silmitasertib, SLV213, RUTI® vaccine, Olokizumab + RPH-104, Mesenchymal stem cell (ADR-001), CYT107, Apabetalone, RTB101, RSLV-132, RBT-9, GRAd-COV2, REGN-COV2 Antibody Cocktail, ABC 294640, Upamostat, Mesenchymal Stromal Cells, Bardoxolone methyl, Telacebec, IQC-950AN, LYT-100, PUL-042, PTC-299, PLX-PAD, PLN-74809, Conestat alfa, Treamid, Melatonin, LTX-109, Selenium, Ramipril, PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, mRNA-1273, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, COVID-19 convalescent plasma, LB1148, Mavrilimumab, and others.
  • November 2023: AstraZeneca announced a study of Phase 3 clinical trials for AZD7442. This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.
  • November 2023: BioNTech SE announced a study of Phase 1 clinical trials for BNT162b4 5 µg. The trial will use a staggered dosing process schema, i.e., enrollment into the next higher dose level is done sequentially and subject to safety data from the previous dose levels, with sentinel participants in Cohorts 1, 2, 3a, and 4a. Cohort 3b investigating the same dose level as Cohort 3a but in participants aged >55 years will be opened after safety data for participants aged 18-55 years in Cohort 3a has been reviewed.

 

Request a sample and discover the recent advances in COVID-19 Drugs @ COVID-19 Competitive Landscape Report

 

The COVID-19 report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the COVID-19 report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.

 

COVID-19 Overview

Coronaviruses are a large family of viruses that can cause illness in animals or humans. In humans several known coronaviruses cause respiratory infections. These coronaviruses range from the common cold to more severe diseases such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19.

 

Find out more about COVID-19 Analytical Perspective: In-depth Commercial Assessment @ COVID-19 Collaboration Analysis by Companies

 

COVID-19 Companies and Therapies

  • Nobelpharma: Sargramostim
  • Staidson (Beijing) Biopharmaceuticals Co., Ltd: BDB-001
  • NeuroActiva Inc.: NA-831
  • Nanogen Pharmaceutical Biotechnology: Nanocovax

 

COVID-19 Competitive Landscape

The COVID-19 report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

COVID-19 Report Assessment

  • Company Analysis
  • COVID-19 Therapeutic Assessment
  • COVID-19 Pipeline Assessment
  • Inactive drugs assessment
  • COVID-19 Unmet Needs

 

Learn more about the emerging COVID-19 Competitive Landscape @ COVID-19 Market Drivers and Barriers, Unmet Needs

 

Scope of the COVID-19 Report

  • Coverage- Global
  • COVID-19 Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
  • COVID-19 Companies- Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, Inc., Valneva, Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories, UNION Therapeutics, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma, TC BioPharm, Syntax for Science, S.L, SyneuRx, Swedish Orphan Biovitrum, Swedish Herbal Institute AB, Stemedica Cell Technologies, Staidson (Beijing) Biopharmaceuticals Co., Ltd, Sound Pharmaceuticals, Sorrento Therapeutics, SolAeroMed, SK Bioscience, Sinovac Biotech Co., Ltd, Sinocelltech, Shenzhen Kangtai Biological Products Co., Ltd., Shaperon, Senhwa Biosciences, Inc., Selva Therapeutics, Archivel Farma, R-Pharm, Rohto Pharmaceutical, Revimmune, Resverlogix Corporation, Restorbio, Resolve Therapeutics, Renibus Therapeutics, ReiThera, Regeneron Pharmaceuticals, RedHill Biopharma, Red de Terapia Celular, Reata Pharmaceuticals, Inc., Qurient Co, Quercis Pharma, PureTech, Pulmotect, PTC Therapeutics, Pluristem Ltd., Pliant Therapeutics, Pharming Technologies B.V., Pharmenterprises, Pharmamel S.L., Pharma Holdings, Pharco Pharmaceuticals, Pfizer, Petrovax, Paion UK Ltd., Ashvattha Therapeutics, Inc. (Orpheris), OPKO Health, Oncotelic Inc., National Resilience, Inc. (Ology Bioservices), Olatec Therapeutics LLC, Novavax, Novartis Pharmaceuticals, Notitia Biotechnologies Company, Noorik Biopharmaceuticals, Nobelpharma, Moderna, Moderna, MetrioPharm, Merck Sharp & Dohme Corp., Merck KGaA, Medicago Inc., Mallinckrodt, Mabwell (Shanghai) Bioscience Co., Ltd., Lifefactors Zona Franca, Leading BioSciences, Kiniksa Pharmaceuticals, Ltd., 3M, 4D Pharma, AbbVie, Apotex, AgelessRx, AgenTus Therapeutics, AiCuris, AlloVir, Apeiron Biologics, Bausch Health Americas, BeiGene, Biotest, Bio-Thera Solutions, Cadila Healthcare Limited, Cellenkos, Cellularity Incorporated, Chiesi Farmaceutici S.p.A., Clene Nanomedicine, Codagenix, Debiopharm, Direct Biologics, Eiger BioPharmaceuticals, Emergent Biosolutions, Enlivex Therapeutics, Evergreen Therapeutics, Faron Pharmaceuticals, Frontier Biotechnologies, FSD Pharma, Genentech, Inc., Globavir Biosciences, Grand Medical, Grifols Therapeutics LLC, Inotrem, Ionis Pharmaceuticals, Jazz Pharmaceuticals, Kamada, Kiadis Pharma, Medicine Invention, MedRegen LLC, Miltenyi Biomedicine, Natureceuticals Sdn Bhd, NeoImmune Tech, Neutrolis, Ology Bioservices, Oncovir, OPKO Health, Organicell Regenerative Medicine, and others.
  • COVID-19 therapies- XAV-19, Sinapultide, VIR-7831, Maraviroc, Duvelisib, VB 201, AV-001, VLA2001, T3 solution for injection, UNIKINON, UNI911, Umbilical cord derived mesenchymal stem cells, MAD0004J08, Stem Cell Educator therapy, RESP301, TD-0903, TCB008, Bemiparin, Pentarlandir™ UPPTA, Emapalumab, Kan Jang capsules, hMSC, BDB-001, Ebselen, COVI-DROPS| Placebo, STI-5656, COVI-AMG, PSC-04, S-1226, GBP510, SARS-COV-2 inactivated vaccine, SCTA01, SARS-CoV-2 Vaccine (Vero Cells), Inactivated, NuSepin, Silmitasertib, SLV213, RUTI® vaccine, Olokizumab + RPH-104, Mesenchymal stem cell (ADR-001), CYT107, Apabetalone, RTB101, RSLV-132, RBT-9, GRAd-COV2, REGN-COV2 Antibody Cocktail, ABC 294640, Upamostat, Mesenchymal Stromal Cells, Bardoxolone methyl, Telacebec, IQC-950AN, LYT-100, PUL-042, PTC-299, PLX-PAD, PLN-74809, Conestat alfa, Treamid, Melatonin, LTX-109, Selenium, Ramipril, PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, mRNA-1273, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, COVID-19 convalescent plasma, LB1148, Mavrilimumab, and others.

  

Dive deep into rich insights for new drugs for COVID-19 Product Developmental Activities, Visit @ COVID-19 Research and Development Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. COVID-19: Overview
  4. COVID-19 -Analytical Perspective: In-depth Commercial Assessment
  5. Competitive Landscape
  6. Therapeutic Assessment
  7. COVID-19: Company and Product Profiles (Marketed Therapies)
  8. AstraZeneca
  9. AZD1222
  10. COVID-19: Company and Product Profiles (Pipeline Therapies)
  11. Late Stage Products (Phase III)
  12. Vicore Pharma
  13. C21
  14. Drug profiles in the detailed report…..
  15. Mid Stage Products (Phase II)
  16. Company Name
  17. Product Name
  18. Drug profiles in the detailed report…..
  19. Early Stage Products (Phase I)
  20. Enanta Pharmaceuticals
  21. EDP 235
  22. Drug profiles in the detailed report…..
  23. Preclinical and Discovery Stage Products
  24. Company Name
  25. Product Name
  26. Drug profiles in the detailed report…..
  27. Inactive Products
  28. COVID-19- Unmet needs
  29. COVID-19 – Market drivers and barriers
  30. Appendix

 

For further information on the COVID-19 Report @ COVID-19 Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: COVID-19 Competitive Landscape 2023 (Updated)

360Wise Media and McDonald’s Celebrate Success of “Faces of Black History” Campaign with Over 2 Million Event Visits

360Wise Media and McDonald's Celebrate Success of "Faces of Black History" Campaign with Over 2 Million Event Visits

“We are thrilled by the incredible response to the ‘Faces of Black History’ campaign,” said Robert Alexander, CEO of 360Wise Media. “This campaign was a labor of love, and we are grateful to McDonald’s for their partnership and support. Together, we were able to create a meaningful and impactful experience that resonated with millions of people across the country.”
In a groundbreaking partnership, 360Wise Media and McDonald’s are thrilled to announce the outstanding success of the “Faces of Black History” campaign. This innovative campaign, designed to honor and celebrate the contributions of African Americans to culture, history, and society, has garnered over 2 million event visits nationwide.

360Wise Media, in partnership with McDonald’s, is proud to announce the overwhelming success of the “Faces of Black History” campaign, which attracted over 2 million event visits nationwide, as confirmed by Google Analytics GA4.

The “Faces of Black History” campaign was launched to honor and celebrate the contributions of Black Americans to culture, history, and society. Through a series of engaging events and initiatives, the campaign highlighted the achievements of Black leaders, artists, activists, and entrepreneurs, inspiring audiences to learn, reflect, and take action.

“We are thrilled by the incredible response to the ‘Faces of Black History’ campaign,” said Robert Alexander, CEO of 360Wise Media. “This campaign was a labor of love, and we are grateful to McDonald’s for their partnership and support. Together, we were able to create a meaningful and impactful experience that resonated with millions of people across the country.”

The success of the “Faces of Black History” campaign is a testament to the power of storytelling and community engagement. By sharing stories of resilience, triumph, and achievement, the campaign sparked conversations, fostered connections, and inspired individuals to celebrate Black history not just during Black History Month, but every day of the year.

“We are incredibly proud of the impact that the ‘Faces of Black History’ campaign has had on our communities,” said, McDonald’s Faces of Black History Tour Manager Terry Gadson, Chief Operating Oficer at Irving Street Rep. “At McDonald’s, we believe in the importance of celebrating diversity and inclusion, and this campaign allowed us to do just that. We look forward to continuing our partnership with 360Wise Media and creating more meaningful experiences for our customers.”

As the “Faces of Black History” campaign comes to a close, 360Wise Media and McDonald’s are already looking ahead to future collaborations. Together, they remain committed to celebrating diversity, promoting inclusion, and honoring the rich tapestry of Black history and culture.

 

Media Contact
Company Name: 360Wise Media
Contact Person: Robert Alexander
Email: Send Email
Phone: 1-844-360-9473
Address:1200 Brickell Ave suite 1950
City: Miami
State: Florida
Country: United States
Website: https://360Wise.com